Joel Greenblatt’s Travere Therapeutics TVTX Stock Holding History

Joel Greenblatt’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Sell	27,628 -749	-3%	-$33.2K	﹤0.01%	1225
2026 Q1	$843K	Sell	28,377 -27,607	-49%	-$825K	﹤0.01%	1361
2025 Q4	$2.14M	Buy	55,984 +28,241	+102%	+$918K	0.01%	1021
2025 Q3	$663K	Buy	+27,743	New	+$522K	﹤0.01%	1321
2015 Q4	–	Sell	-25,289	Closed	-$512K	–	1017
2015 Q3	$512K	Buy	25,289 +8,307	+49%	+$246K	0.01%	723
2015 Q2	$563K	Buy	+16,982	New	+$465K	﹤0.01%	717

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's TVTX Position: Q2 2026 in Review

Joel Greenblatt reduced its Travere Therapeutics (TVTX) stake by 2.6% in Q2 2026, selling an estimated $33.2K and leaving 27,628 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1225.

Joel Greenblatt first reported a position in TVTX in Q2 2015 and has held it in 6 quarters since. The position peaked at $2.14M in Q4 2025. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Joel Greenblatt held 27,628 shares of Travere Therapeutics worth $1.57M as of Q2 2026.
Joel Greenblatt sold 749 Travere Therapeutics shares in Q2 2026, an estimated $33.2K.
Travere Therapeutics made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1225 holding.
Joel Greenblatt first reported a position in Travere Therapeutics in Q2 2015 and has held it in 6 quarters since.
Joel Greenblatt's Travere Therapeutics position peaked at $2.14M in Q4 2025.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.